Among the identified subtypes, armored & cold tumors exhibited the most favorable response to ICB across various cancer types.[8] In addition, an unbiased approach highlighted potential drug targets, primarily stromal proteins such as B7‐H3 and vascularization markers, which are highly expressed in armored & cold tumors and could be leveraged for targeted therapy.[8]. Here, CD276 is linked to cancer.